Author: Sanidas, Elias; Grassos, Charalampos; Papadopoulos, Dimitrios; Velliou, Maria; Barbetseas, John
Title: Pulmonary Embolism Prophylaxis in Patients with COVID-19: An Emerging Issue Cord-id: mshd6xef Document date: 2021_5_12
ID: mshd6xef
Snippet: Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected dise
Document: Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.
Search related documents:
Co phrase search for related documents- abnormal chest imaging and admission prior: 1
- acquire syndrome and acute respiratory syndrome: 1, 2, 3, 4, 5
- activator inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activator inhibitor and lmwh low molecular weight heparin: 1
- active cancer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active cancer and admission prior: 1, 2, 3
- active cancer and lopinavir ritonavir: 1, 2, 3
- active cancer and low incidence: 1, 2
- acute ards respiratory disease syndrome and lopinavir ritonavir: 1, 2, 3, 4
- acute ards respiratory disease syndrome and low incidence: 1
- acute respiratory syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission prior and lmwh low molecular weight heparin: 1, 2
- admission prior and lopinavir ritonavir: 1, 2, 3, 4
- lmwh low molecular weight heparin and lopinavir ritonavir: 1, 2, 3
- lmwh low molecular weight heparin and low incidence: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date